Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/ercc1-mrna-expression-is-not-associated-with-response-and-survival-PJNoRC9cHf
References (30)
-
D. Siegel, A. Anwar, S. Winski, J. Kepa, Kathryn Zolman, David Ross (2001)
Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1.Molecular pharmacology, 59 2
-
M. Kartalou, J. Essigmann (2001)
Mechanisms of resistance to cisplatin.Mutation research, 478 1-2
-
C. Ramakers, J. Ruijter, R. Deprez, A. Moorman (2003)
Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) dataNeuroscience Letters, 339
-
(2000)
Low thymidylate synthetase and ERCC1 gene expression are associated with increased survival after neoadjuvant 5-FU/cisplatin/radiotherapy for oesophageal adenocarcinoma (Abstract) -
R. Lord, J. Brabender, D. Gandara, V. Alberola, C. Camps, M. Dómine, F. Cardenal, J. Sánchez, P. Gumerlock, M. Taron, J. Sánchez, K. Danenberg, P. Danenberg, R. Rosell (2002)
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 7
-
(2001)
Quantitative ERCC1 RNA expression identifies non-response to cis-platinum based neoadjuvant radiochemotherapy for esophageal cancer (Abstract) -
M. Dabholkar, J. Vionnet, F. Bostick-Bruton, J. Yu, E. Reed (1994)
Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.The Journal of clinical investigation, 94 2
-
R. Metzger, C. Leichman, K. Danenberg, P. Danenberg, H. Lenz, K. Hayashi, S. Groshen, D. Salonga, H. Cohen, L. Laine, P. Crookes, H. Silberman, J. Baranda, Brahma Konda, L. Leichman (1998)
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 1
-
R. Booton, P. Lorigan, H. Anderson, S. Baka, L. Ashcroft, M. Nicolson, M. O'brien, D. Dunlop, K. O'Byrne, V. Laurence, M. Snee, G. Dark, N. Thatcher (2006)
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1).Annals of oncology : official journal of the European Society for Medical Oncology, 17 7
-
J. Schiller, D. Harrington, C. Belani, C. Langer, A. Sandler, J. Krook, Junming Zhu, David Johnson (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.The New England journal of medicine, 346 2
-
L. Cheng, Y. Guan, L. Li, R. Legerski, J. Einspahr, J. Bangert, D. Alberts, Q. Wei (1999)
Expression in normal human tissues of five nucleotide excision repair genes measured simultaneously by multiplex reverse transcription-polymerase chain reaction.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 8 9
-
K. Shibuya, C. Mathers, C. Boschi-Pinto, Alan Lopez, C. Murray (2002)
Global and regional estimates of cancer mortality and incidence by site: II. results for the global burden of disease 2000BMC Cancer, 2
-
K. Lee, R. Parker, V. Bohr, T. Cornelison, E. Reed (1993)
Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.Carcinogenesis, 14 10
-
Shirley Smith, Naomi Bowers, Daniel Betticher, Oliver Gautschi, D. Ratschiller, Paul Hoban, R. Booton, Mauro Santibanez-Koref, J. Heighway (2005)
Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instabilityBritish Journal of Cancer, 93
-
J. Heighway, Teresa Knapp, L. Boyce, S. Brennand, J. Field, D. Betticher, D. Ratschiller, M. Gugger, M. Donovan, A. Lasek, P. Rickert (2002)
Expression profiling of primary non-small cell lung cancer for target identificationOncogene, 21
-
K. Ferry, Thomas Hamilton, Steven Johnson (2000)
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.Biochemical pharmacology, 60 9
-
K. Olaussen, A. Dunant, P. Fouret, E. Brambilla, F. André, V. Haddad, E. Taranchon, M. Filipits, R. Pirker, H. Popper, R. Stahel, L. Sabatier, J. Pignon, T. Tursz, T. Chevalier, J. Soria (2006)
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.The New England journal of medicine, 355 10
-
R. Britten, Dan-dan Liu, Amy Tessier, Michael Hutchison, D. Murray (2000)
ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cellsInternational Journal of Cancer, 89
-
Bridget Hill, Kevin Scanlon, J. Hansson, A. Harstrick, Martin Pera, A. Fichtinger-Schepman, S. Shellard (1994)
Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients.European journal of cancer, 30A 6
-
Q. Li, L. Ding, E. Reed (2000)
Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells.Research communications in molecular pathology and pharmacology, 107 5-6
-
J. Moggs, K. Yarema, J. Essigmann, R. Wood (1996)
Analysis of Incision Sites Produced by Human Cell Extracts and Purified Proteins during Nucleotide Excision Repair of a 1,3-Intrastrand d(GpTpG)-Cisplatin Adduct (*)The Journal of Biological Chemistry, 271
-
Quentin Li, Jing Yu, C. Mu, M. Yunmbam, D. Slavsky, C. Cross, F. Bostick-Bruton, Eddie Reed (2000)
Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.Anticancer research, 20 2A
-
Inusha Silva, P. McHugh, P. Clingen, J. Hartley (2000)
Defining the Roles of Nucleotide Excision Repair and Recombination in the Repair of DNA Interstrand Cross-Links in Mammalian CellsMolecular and Cellular Biology, 20
-
S. Goto, T. Iida, Sungsam Cho, M. Oka, S. Kohno, T. Kondo (1999)
Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells.Free radical research, 31 6
-
M. Dabholkar, M. Berger, J. Vionnet, C. Egwuagu, J. Silber, J. Yu, E. Reed (1995)
Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2.Cancer research, 55 6
-
M. Zdzienicka, L. Roza, A. Westerveld, Dirk Bootsma, J. Simons (1987)
Biological and biochemical consequences of the human ERCC-1 repair gene after transfection into a repair-deficient CHO cell line.Mutation research, 183 1
-
I. Song, N. Savaraj, Z. Siddik, Peiman Liu, Yingjie Wei, Chunjing Wu, M. Kuo (2004)
Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.Molecular cancer therapeutics, 3 12
-
Mazin Moufarij, D. Phillips, C. Cullinane (2003)
Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.Molecular pharmacology, 63 4
-
P. Ceppi, M. Volante, S. Novello, I. Rapa, K. Danenberg, P. Danenberg, A. Cambieri, G. Selvaggi, S. Saviozzi, R. Calogero, M. Papotti, G. Scagliotti (2006)
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.Annals of oncology : official journal of the European Society for Medical Oncology, 17 12
-
R. Booton, T. Ward, J. Heighway, P. Taylor, F. Power, L. Ashcroft, Julie Morris, N. Thatcher (2006)
Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum‐based chemotherapy in advanced nonsmall cell lung cancerCancer, 106
- ISSN
- 1556-0864
- DOI
- 10.1097/JTO.0b013e318155a637
- pmid
- 17909351
- Publisher site
- See Article on Publisher Site
Abstract
ORIGINAL ARTICLES ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer Richard Booton, PhD, MRCP,* Tim Ward, PhD,* Linda Ashcroft, BSc,* Julie Morris, PhD,† Jim Heighway, PhD,‡ and Nick Thatcher, PhD, FRCP*† ost patients with lung cancer present at a stage at which Background: Platinum-based therapy is pivotal to the treatment of Mcurrent cytotoxic regimens are generally not suffi- advanced non-small cell lung Cancer (NSCLC). Excision repair ciently effective to deliver curative treatment; consequently, cross-complementation group 1 (ERCC1) is a key component of the this common disease remains the leading cause of cancer- platinum-DNA repair machinery responsible for nucleotide excision related death worldwide. Platinum-based chemotherapy is a repair. We sought to determine the influence of ERCC1 mRNA pivotal treatment in the management of advanced non-small expression in advanced NSCLC on chemotherapy response, toxicity, 2 cell lung cancer (NSCLC), but current standard practice only and survival after platinum-based chemotherapy. attains a median survival of approximately 8 months. Plati- Methods: Patients randomized to a phase III trial of platinum-based num drugs exert their cytotoxicity by forming platinum-DNA chemotherapy were eligible for inclusion. Formalin-fixed paraffin- adducts and, subsequently, intra- and less
Journal
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Oct 1, 2007